- The agreement will see The Herb Clinic refer medical cannabis patients to Ayurcann through a patient education agreement
- Ayurcann will work with the patients to educate them on their available offerings and help them select appropriate products
- The Herb Clinic has over 4000 patients registered and is comprised of compassionate and knowledgeable service providers
- Ayurcann Holdings is a provider of customized post-harvest outsourcing solutions to licensed cannabis producers
- Ayurcann Holdings Corp. (AYUR) is down 2.63 per cent, trading at C$0.185 per share at 10:15 am ET
Ayurcann Holdings (AYUR) has entered into a patient-referral agreement with The Herb Clinic.
The Herb Clinic has over 4000 patients registered and is comprised of compassionate and knowledgeable service providers who are defined by their ability to provide exceptional patient care. They help educate and integrate cannabis into the patient’s medical treatment plans and partner with medicinal cannabis providers such as Ayurcann, to ensure their patients are getting top-quality advice with exceptional value.
The agreement will see The Herb Clinic refer medical cannabis patients to Ayurcann through a patient education agreement. Ayurcann will work with the patients to educate them on their available offerings and help them select appropriate products.
Igal Sudman, CEO of Ayurcann commented on the partnership with The Herb Clinic.
“Working with the leaders in the industry is what we strive towards, being able to partner with and enhance cannabis education, provide the best possible value, national coverage, while expending our offerings for the best national and international brands for THC and CBD based products to patients is making Ayurcann a leader in the industry.”
Ayurcann is focused on becoming the partner of choice for Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.
Ayurcann Holdings Corp. (AYUR) is down 2.63 per cent, trading at C$0.185 per share at 10:15 am ET.
